People In Brief
This article was originally published in The Gray Sheet
Executive Summary
FDA external relations: FDA Assistant Commissioner for Public Affairs Lawrence Bachorik will serve as acting associate commissioner for external relations, succeeding Peter Pitts, who left the agency for the public relations firm of Manning Selvage & Lee June 18 (1"The Gray Sheet" June 7, 2004, p. 24). Bachorik has headed FDA's public affairs office since February 2000. FDA Senior Director for Media Affairs Brad Stone will fill in for Bachorik as acting assistant commissioner for public affairs...
You may also be interested in...
People In Brief
FDA external relations: Agency names Mayer, Brown, Rowe & Maw attorney Sheila Walcoff to succeed Peter Pitts as associate commissioner for external relations (1"The Gray Sheet" June 28, 2004, p. 4). In her new role, Walcoff will advise Acting Commissioner Lester Crawford on legal policy and program direction for FDA's interactions with stakeholders and other external audiences, as well as supervise the agency's Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues and the Advisory Committee Oversight and Management Staff. Lawrence Bachorik, who had been filling in for Pitts, will return to his role as FDA assistant commissioner for public affairs...
People In Brief
FDA external relations: Agency names Mayer, Brown, Rowe & Maw attorney Sheila Walcoff to succeed Peter Pitts as associate commissioner for external relations (1"The Gray Sheet" June 28, 2004, p. 4). In her new role, Walcoff will advise Acting Commissioner Lester Crawford on legal policy and program direction for FDA's interactions with stakeholders and other external audiences, as well as supervise the agency's Office of Public Affairs, Office of the Ombudsman, Office of Special Health Issues and the Advisory Committee Oversight and Management Staff. Lawrence Bachorik, who had been filling in for Pitts, will return to his role as FDA assistant commissioner for public affairs...
People In Brief
Cerus brings in new blood: William Dawson joins firm Aug. 9 as chief financial officer. Previously, Dawson served as CFO at biopharmaceutical firm Dynavax Technologies Corp., where he spearheaded the creation and $61 mil. IPO of Dynavax Asia. Dawson replaces Gregory Schafer, who had been Cerus' CFO since 1999. Cerus recently inked a marketing and distribution agreement with BioOne Corp for Asian commercialization of its Intercept blood system for pathogen inactivation. The Concord, Calif.-based concern's efforts to bring Intercept to the U.S. market encountered delays when it chose to halt its Phase III trial for the red blood cell pathogen reduction program after two patients developed antibodies (1"The Gray Sheet" March 29, 2004, p. 14)...